In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Study shows longer-term benefit of one-month dual antiplatelet therapy after intervention

MASTER DAPT trial presented in a Hot Line Session today at ESC Congress 2022

Cardiovascular Pharmacotherapy

Barcelona, Spain – 29 Aug 2022: A prespecified analysis of the MASTER DAPT trial has confirmed that the absence of ischaemic risk and reduction in bleeding with abbreviated dual antiplatelet therapy (DAPT) in patients at high bleeding risk undergoing intervention persists beyond one year of follow up. The late breaking research is presented in a Hot Line session today at ESC Congress 2022.1

Professor Marco Valgimigli of the Cardiocentro Ticino Foundation, Lugano, Switzerland said: “The findings reinforce the need to identify patients at high bleeding risk undergoing percutaneous coronary intervention (PCI) so that upfront decisions can be made on antiplatelet treatment and duration to mitigate bleeding risk and optimise outcomes.”

In MASTER DAPT, patients with acute or chronic coronary syndrome at high bleeding risk underwent PCI with biodegradable polymer sirolimus-eluting stents. Patients free from ischaemic and bleeding events and who adhered to a DAPT regimen at one month after PCI were randomised to immediate DAPT discontinuation versus treatment continuation for up to one year. One-month DAPT was noninferior for net and major adverse cardiac or cerebrovascular events and was associated with lower major or clinically relevant nonmajor bleeding at 11 months.2

Following the 12-month trial, patients in both treatment groups received routine clinical care at the discretion of their physician. The researchers recorded medications and adverse events during the following three months, and the results of the prespecified 15-month final analysis are reported today. Of 2,295 and 2,284 patients randomised to abbreviated versus standard DAPT, 2,205 and 2,186 patients started routine care at 12 months, respectively. Complete follow-up at 15 months was available for 99.8% and 99.9% of patients in the abbreviated and standard arms, respectively.

For routine care, physicians tended to continue the treatment assigned in the trial. Guidelines3,4 recommend that patients not on oral anticoagulation (OAC) should discontinue DAPT, but more than 15% of non-OAC patients were still on DAPT at 15 months in the standard DAPT arm, which was approximately three times higher than the corresponding figure in the abbreviated arm. Similarly, although guidelines recommend that OAC patients, if free from recurrent ischaemic events or repeat interventions, should discontinue single antiplatelet therapy (SAPT), more than one fourth were still on SAPT in the standard DAPT arm compared with 14% of the abbreviated treatment group. In multivariate modelling, prior allocation to abbreviated treatment was a strong independent predictor of SAPT versus DAPT in non-OAC patients and no antiplatelet versus SAPT in OAC patients.

Professor Valgimigli said: “We also found that except for age, bleeding risk did not affect the choice of DAPT versus SAPT, nor did prior bleeding. In contrast, clinical or procedural markers of ischaemic risk drove clinicians to prolong DAPT beyond one year.”

The researchers reported 15-month results according to original treatment assignment for the three coprimary outcomes of the main trial: 1) net adverse clinical events (NACE; composite of all-cause death, myocardial infarction, stroke, and major or clinically relevant nonmajor bleeding); 2) major adverse cardiac and cerebral events (MACCE; composite of all-cause death, myocardial infarction, and stroke); and 3) major or clinically relevant nonmajor bleeding (Bleeding Academic Research Consortium type 2, 3 or 5 bleeding).

NACE occurred in 199 (8.7%) and 214 (9.5%) patients in the abbreviated and standard DAPT groups, respectively, for a hazard ratio (HR) of 0.92 (95% confidence interval [CI] 0.76–1.12; p=0.399) and a risk difference of −0.75 percentage points (95% CI −2.42 to 0.93). MACCE occurred in 158 (6.9%) and 167 (7.4%) patients in the abbreviated and standard DAPT arms, respectively (HR 0.94; 95% CI 0.76–1.17; p=0.579), for a risk difference of −0.51 percentage points (95% CI −2.01 to 1.00). Major or clinically relevant nonmajor bleeding remained lower in the abbreviated compared with the standard therapy arm (167 [7.4%] versus 239 [10.7%]; HR 0.68; 95% CI 0.56–0.83; p=0.0001), for a risk difference of −3.25 percentage points (95% CI −4.93 to -1.58).

Professor Valgimigli said: “We found that when DAPT or SAPT is prescribed, that treatment tends to continue for longer than recommended. This unexpected finding may explain the consistency of treatment effects between the randomised and routine care phases of our study. It also indicates the need to clearly define therapy duration upfront to avoid potentially unnecessary treatment.”



Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.


This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.


Funding: The study was sponsored by the European Cardiovascular Research Institute, a non-profit organisation, and received grant support from Terumo.


Disclosures: Marco Valgimigli received consulting or speaker fees from AstraZeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, IDORSIA PHARMACEUTICALS LTD, Universität Basel | Dept. Klinische Forschung, Vifor, Bristol Myers Squibb SA, Biotronik, Boston Scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, ECRI.


References and notes

1MASTER DAPT will be discussed during Hot Line Session 8 on Monday 29 August at 08:30 to 10:00 CEST in the Barcelona auditorium.

2Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385:1643–1655.

3Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–1367.

4Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213–254.


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at